Literature DB >> 17374882

Effect of deletion of the lpxM gene on virulence and vaccine potential of Yersinia pestis in mice.

Andrey P Anisimov1, Rima Z Shaikhutdinova1, Lyudmila N Pan'kina2, Valentina A Feodorova2, Elena P Savostina2, Ol'ga V Bystrova3, Buko Lindner4, Aleksandr N Mokrievich1, Irina V Bakhteeva1, Galina M Titareva1, Svetlana V Dentovskaya1, Nina A Kocharova3, Sof'ya N Senchenkova3, Otto Holst4, Zurab L Devdariani2, Yuriy A Popov2, Gerald B Pier5, Yuriy A Knirel3.   

Abstract

Yersinia pestis undergoes an obligate flea-rodent-flea enzootic life cycle. The rapidly fatal properties of Y. pestis are responsible for the organism's sustained survival in natural plague foci. Lipopolysaccharide (LPS) plays several roles in Y. pestis pathogenesis, prominent among them being resistance to host immune effectors and induction of a septic-shock state during the terminal phases of infection. LPS is acylated with 4-6 fatty acids, the number varying with growth temperature and affecting the molecule's toxic properties. Y. pestis mutants were constructed with a deletion insertion in the lpxM gene in both virulent and attenuated strains, preventing the organisms from synthesizing the most toxic hexa-acylated lipid A molecule when grown at 25 degrees C. The virulence and/or protective potency of pathogenic and attenuated Y. pestis DeltalpxM mutants were then examined in a mouse model. The DeltalpxM mutation in a virulent strain led to no change in the LD(50) value compared to that of the parental strain, while the DeltalpxM mutation in attenuated strains led to a modest 2.5-16-fold reduction in virulence. LPS preparations containing fully hexa-acylated lipid A were ten times more toxic in actinomycin D-treated mice then preparations lacking this lipid A isoform, although this was not significant (P>0.05). The DeltalpxM mutation in vaccine strain EV caused a significant increase in its protective potency. These studies suggest there is little impact from lipid A modifications on the virulence of Y. pestis strains but there are potential improvements in the protective properties in attenuated vaccine strains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374882     DOI: 10.1099/jmm.0.46880-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  17 in total

1.  Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens.

Authors:  V A Feodorova; L N Pan'kina; E P Savostina; O S Kuznetsov; N P Konnov; L V Sayapina; S V Dentovskaya; R Z Shaikhutdinova; S A Ageev; B Lindner; A N Kondakova; O V Bystrova; N A Kocharova; S N Senchenkova; O Holst; G B Pier; Y A Knirel; A P Anisimov; V L Motin
Journal:  Vaccine       Date:  2009-02-13       Impact factor: 3.641

2.  Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism.

Authors:  Dustin Dovala; Christopher M Rath; Qijun Hu; William S Sawyer; Steven Shia; Robert A Elling; Mark S Knapp; Louis E Metzger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-28       Impact factor: 11.205

3.  Mutually constructive roles of Ail and LPS in Yersinia pestis serum survival.

Authors:  Chandan Singh; Hwayoung Lee; Ye Tian; Sara Schesser Bartra; Suzanne Hower; Lynn M Fujimoto; Yong Yao; Sergey A Ivanov; Rima Z Shaikhutdinova; Andrey P Anisimov; Gregory V Plano; Wonpil Im; Francesca M Marassi
Journal:  Mol Microbiol       Date:  2020-06-25       Impact factor: 3.501

4.  Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium.

Authors:  Jian Sha; Michelle L Kirtley; Christina J van Lier; Shaofei Wang; Tatiana E Erova; Elena V Kozlova; Anthony Cao; Yingzi Cong; Eric C Fitts; Jason A Rosenzweig; Ashok K Chopra
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

5.  Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague.

Authors:  Bethany L Tiner; Jian Sha; Michelle L Kirtley; Tatiana E Erova; Vsevolod L Popov; Wallace B Baze; Christina J van Lier; Duraisamy Ponnusamy; Jourdan A Andersson; Vladimir L Motin; Sadhana Chauhan; Ashok K Chopra
Journal:  Infect Immun       Date:  2015-01-20       Impact factor: 3.441

6.  Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Authors:  Ryan T Ranallo; Robert W Kaminski; Tonia George; Alexis A Kordis; Qing Chen; Kathleen Szabo; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

7.  Pathogenicity of Yersinia pestis synthesis of 1-dephosphorylated lipid A.

Authors:  Wei Sun; David A Six; C Michael Reynolds; Hak Suk Chung; Christian R H Raetz; Roy Curtiss
Journal:  Infect Immun       Date:  2013-01-28       Impact factor: 3.441

8.  Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.

Authors:  Bethany L Tiner; Jian Sha; Duraisamy Ponnusamy; Wallace B Baze; Eric C Fitts; Vsevolod L Popov; Christina J van Lier; Tatiana E Erova; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2015-10-07

9.  Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques.

Authors:  Qingwen Zhang; Qiong Wang; Guang Tian; Zhizhen Qi; Xuecan Zhang; Xiaohong Wu; Yefeng Qiu; Yujing Bi; Xiaoyan Yang; Youquan Xin; Jian He; Jiyuan Zhou; Lin Zeng; Ruifu Yang; Xiaoyi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-11-13       Impact factor: 3.452

Review 10.  Rational considerations about development of live attenuated Yersinia pestis vaccines.

Authors:  Wei Sun; Roy Curtiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.